BIRMINGHAM, Ala. (WIAT) -- The Mike Slive Foundation has named the recipients of six prostate cancer research grants.
The grants are aimed at continuing the foundation's stated mission of ending prostate cancer. 39 prostate cancers research grants have been awarded by the foundation since it began in 2017.
“My father was the recipient of a clinical trial during his prostate cancer treatment,” said Anna Slive Harwood, Executive Director of the Mike Slive Foundation. “The research we fund aims to address all aspects of prostate cancer detection and treatment, ranging from initial diagnosis to improving quality of life for patients and survivors. We’re so proud to invest funds in these grants that we hope will get us closer to eradicating prostate cancer in our lifetime.”
The Mike Slive Foundation 2024-25 Research Grant Recipients include:
- PSMA targeted sialidase for prostate cancer immunotherapy, Dr. James D. Brooks, Stanford University.
- Harnessing TMPRSS2-ERG Fusion-Derived Neoantigens for an Off-the-Shelf Prostate Cancer Vaccine, Dr. Nina Bhardwaj and Dr. Mesude Bicak, Icahn School of Medicine at Mount Sinai.
- Targeting dopa decarboxylase (DDC)-dependent metabolic reprogramming to overcome immunotherapy resistance in NEPC, Dr. Guocan Wang, The University of Texas MD Anderson Cancer Center.
- Investigating PTGES3 as a Novel Therapeutic Target in Advanced Prostate Cancer, Dr. Haolong Li, Fred Hutchinson Cancer Center.
- Murine Modeling and Immunotherapeutic Targeting of GPC3 Positive Prostate Cancer, Dr. Christopher J. Pirozzi and Dr. Jiaoti Huang, Duke University Medical Center.
Developing CAR-NKT cells to reprogram the Tumor Microenvironment in Prostate Cancer, Tonya J. Webb, University of Maryland, Baltimore.